Tetra Radar · FDA Approvals · Decision date
ANKTIVA: FDA decision date
ImmunityBio, Inc. (IBRX) · 6 January 2027
The FDA accepted for review the company’s sBLA for ANKTIVA indicated with BCG in patients with BCG-unresponsive NMIBC with papillary tumors without CIS and assigned a PDUFA target action date of January 6, 2027.
Source: 10-Q of 4 August 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.